RETAVASE® (reteplase) is a recombinant plasminogen activator which catalyzes the cleavage of endogenous plasminogen to generate plasmin. Plasmin degrades the fibrin matrix of the thrombus, exerting its thrombolytic action.
RETAVASE® (reteplase) pharmacology & MOA
RETAVASE has an effective half-life of 13–16 minutes and is cleared primarily by the liver and kidneys.
|In a controlled trial, 36 of 56 patients treated for myocardial infarction had a decrease in fibrinogen levels to below 100 mg/dL by 2 hours following the administration of RETAVASE as 2 intravenous injections (10 + 10 unit) in which a dose of 10 units was followed 30 minutes later by a second dose of 10 units.|
|In this trial, the mean fibrinogen level returned to the baseline value by 48 hours.|
Mechanism of action1
RETAVASE is a recombinant plasminogen activator. It catalyzes the cleavage of endogenous plasminogen to generate plasmin, which in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.